169 related articles for article (PubMed ID: 25230982)
1. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
[TBL] [Abstract][Full Text] [Related]
4. G250: a carbonic anhydrase IX monoclonal antibody.
Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
[TBL] [Abstract][Full Text] [Related]
5. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
[TBL] [Abstract][Full Text] [Related]
6. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
7. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
8. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
9. The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
Yamaguchi A; Usami K; Shimabe M; Hasegawa K; Asada M; Motoki K; Tahara T; Masuda K
Anticancer Res; 2015 Apr; 35(4):1997-2004. PubMed ID: 25862852
[TBL] [Abstract][Full Text] [Related]
10. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.
Uemura H; Nakagawa Y; Yoshida K; Saga S; Yoshikawa K; Hirao Y; Oosterwijk E
Br J Cancer; 1999 Oct; 81(4):741-6. PubMed ID: 10574265
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX.
Zat'ovicová M; Tarábková K; Svastová E; Gibadulinová A; Mucha V; Jakubícková L; Biesová Z; Rafajová M; Ortova Gut M; Parkkila S; Parkkila AK; Waheed A; Sly WS; Horak I; Pastorek J; Pastoreková S
J Immunol Methods; 2003 Nov; 282(1-2):117-34. PubMed ID: 14604546
[TBL] [Abstract][Full Text] [Related]
12. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
[TBL] [Abstract][Full Text] [Related]
13. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies.
Takacova M; Barathova M; Hulikova A; Ohradanova A; Kopacek J; Parkkila S; Pastorek J; Pastorekova S; Zatovicova M
Int J Oncol; 2007 Nov; 31(5):1103-10. PubMed ID: 17912436
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.
Pastorek J; Pastorekova S
Semin Cancer Biol; 2015 Apr; 31():52-64. PubMed ID: 25117006
[TBL] [Abstract][Full Text] [Related]
17. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
18. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX expression in prostate cancer.
Smyth LG; O'Hurley G; O'Grady A; Fitzpatrick JM; Kay E; Watson RW
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):178-81. PubMed ID: 20038959
[TBL] [Abstract][Full Text] [Related]
20. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy.
Duan Y; Zheng J; Han S; Wu Y; Wang Y; Li D; Kong D; Yu Y
J Control Release; 2008 Apr; 127(2):173-9. PubMed ID: 18316136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
